Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company, focused on the discovery, development, and commercialization of cell therapies for patients with cancer.
The business
Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company, focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its diversified portfolio includes first-in-class autologous CAR T cell therapies and allogeneic natural killer (NK) cell therapies. Its assets are being developed across multiple different disease areas in oncology with four clinical stage programs. Its pipeline includes CHM CDH17, CHM CLTX and CHM CORE NK platform. CHM CDH17 is a third-generation CDH17 CAR T, which is in phase I/II clinical trial in gastrointestinal and neuroendocrine tumors. CHM CORE-NK is a clinically validated NK cell platform in phase IB clinical trials investigating CORE-NK in combination regimens. CHM CLTX is a novel CAR-T therapy developed for the treatment of patients with solid tumors. CLTX CAR T is in phase IB clinical trial in recurrent/progressive glioblastoma. It is also building a Cell therapy portfolio.
Small Caps Research
No research on Chimeric Therapeutics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise CHM based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Chimeric Therapeutics gains FDA fast-track approval for CHM CDH17 gastrointestinal cancer candidate
Chimeric Therapeutics (ASX: CHM) has received fast-track designation from the US Food and Drug Administration (FDA) for lead candidate CHM CDH17 to treat gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The FDA based its designation on the drug’s potential to improve outcomes for patients who have progressed beyond at least one prior line of therapy in the advanced […]
Chimeric Therapeutics receives ethics approval for CHM CDH17 gastrointestinal cancer trial
Chimeric Therapeutics (ASX: CHM) has received ethics approval for the initiation of a multi-site Phase 1/2 clinical trial of CHM CDH17 in patients with advanced gastrointestinal cancers. CHM CDH17 is a third generation novel CAR T cell therapy aimed at a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumours […]
Chimeric Therapeutics secures US patent for groundbreaking ‘killer cell’ cancer therapy
Australian cell therapy specialist Chimeric Therapeutics (ASX:CHM) has achieved another milestone in its efforts to commercialise its CHM 0201 (CORE-NK) “killer cell” technology. Chimeric has received confirmation from the US Patent & Trademark Office (USPTO) that it will allow the issuance of a patent application covering the CHM 0201 technology. CHM 0201 is used to […]
Australian biotech sector tipped for strong growth
Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.